Realizing the full promise of patient centricity in pharma requires transformative change
The business model that’s been the bedrock of the pharmaceutical industry over the last few years—discovering new drugs and commercializing them profitably—has shifted, with growing numbers of industry stakeholders now investing in patient centricity.
In 2018, a global survey of pharmaceutical executives found that 86% ranked delivering on a patient-focused vision among their organization’s top priorities. The rapid changes that have taken place since then have only amplified the need to adopt patient-centric approaches across the life sciences value chain.
Today, it’s more important than ever for biotechnology and pharmaceutical companies to move in this direction—but that doesn’t mean that becoming patient-centric is easy. It involves a fundamental transformation that spans business models, company cultures, ways of collaborating and digitization. This isn’t a small change, and it’s becoming unavoidable.
Our playbook offers a working definition of patient centricity in the life sciences and outlines why patient centricity is more important than ever, the benefits of achieving it, and what it takes to be a patient-centric life sciences organization.
Adopting Digital Mindsets: Where Healthcare Stakeholders Are Succeeding and Where They’re Falling Short
From gut feel to data-driven: Why pricing strategy is critical for high-tech and software firms